

RECEIVED
CENTRAL FAX CENTER

MAR 27 2007

FAX TRANSMISSION

DATE: March 27, 2007

PTO IDENTIFIER: Application Number 10/561,718-Conf. #1123
Patent Number

Inventor: Frank Wu et al.

MESSAGE TO: US Patent and Trademark Office

FAX NUMBER: (571) 273-8300

FROM: EDWARDS ANGELL PALMER & DODGE LLP

Jeffrey D. Hsi

PHONE: (617) 439-4444

Attorney Dkt. #: 61558USN(50530)

PAGES (Including Cover Sheet): 5

CONTENTS: Certificate of Transmission (1 page)
Information Disclosure Statement (2 pages)
IDS (Citation) by Applicant (9 References) (1 page)

If your receipt of this transmission is in error, please notify this firm immediately by collect call to sender at (617) 439-4444 and send the original transmission to us by return mail at the address below.

This transmission is intended for the sole use of the individual and entity to whom it is addressed, and may contain information that is privileged, confidential and exempt from disclosure under applicable law. You are hereby notified that any dissemination, distribution or duplication of this transmission by someone other than the intended addressee or its designated agent is strictly prohibited.

EDWARDS ANGELL PALMER & DODGE LLP
P.O. Box 55874, Boston, Massachusetts 02205
Telephone: (617) 439-4444 Facsimile: (617) 439-4170

RECEIVED
CENTRAL FAX CENTER

MAR 27 2007

PTO/SB/97 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031

U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Application No. (if known): 10/561,718

Attorney Docket No.: 61558USN(50530)

Certificate of Transmission under 37 CFR 1.8

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office.

on March 27, 2007
Date



Signature

Maria Carr

Typed or printed name of person signing Certificate

N/A

Registration Number, if applicable

(617) 439-4444

Telephone Number

Note: Each paper must have its own certificate of transmission, or this certificate must identify each submitted paper.

Information Disclosure Statement (2 pages)
IDS (Citation) by Applicant (9 References) (1 page)

RECEIVED
CENTRAL FAX CENTER

MAR 27 2007

Docket No.: 61558USN(50530)
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Frank Wu et al.

Application No.: 10/561,718

Confirmation No.: 1123

Filed: December 20, 2005

Art Unit: N/A

For: AZA-PEPTIDE MACROCYCLIC
HEPATITIS C SERINE PROTEASE
INHIBITORS

Examiner: Not Yet Assigned

INFORMATION DISCLOSURE STATEMENT (IDS)

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned (37 CFR 1.97(b)(3)).

Those documents which are marked with a double asterisk (**) next to the Cite No. in the attached form PTO/SB/08 are not supplied because they were previously cited by or submitted to the Office in a prior application number 10/613,206, filed July 3, 2003, and relied upon in this application for an earlier filing date under 35 U.S.C. 120.

089408

Application No.: 10/561,718

2

Docket No.: 61558USN(50530)

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 04-1105, under Order No. 61558USN(50530).

Dated: 27 March 2007

Respectfully submitted,

By 

Jeffrey D. Hsi

Registration No.: 40,024

EDWARDS ANGELL PALMER & DODGE
LLP

P.O. Box 55874

Boston, Massachusetts 02205

(617) 439-4444

Attorneys/Agents For Applicant

**RECEIVED
CENTRAL FAX CENTER**

MAR 27 2007

PTO/SB/08A/B (09-06)

Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/561,718-Conf. #1123
				Filing Date	12-20-2005
				First Named Inventor	Frank Wu
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	1	of	1	Attorney Docket Number	61558USN(50530)

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA**	6,329,379	12-2001	Llinas-Brunet et al.	
	AB**	US 2002/0037998 A1	3-28-2002	Llinas-Brunet et al.	
	AC**	6,608,027	8-19-2003	Tsantrizos et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁴
		Country Code ² -Number ³ -Kind Code ² (if known)	MM-DD-YYYY			
	BA**	WO-00/59929-A1	10-12-2000	Boehringer Ingelheim (Canada) Ltd.		
	BB**	WO-00/09543-A2	02-24-2000	Boehringer Ingelheim (Canada) Ltd.		
	BC**	WO-2004/072243-A2	08-26-2004	Enanta Pharmaceuticals, Inc.		
	BD**	WO-03/053349	12-20-2001			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind's Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
	CA*	Weinstein B.: "Chemistry and Biochemistry of Amino Acids, Peptides and Proteins, Passage." Chemistry and Biochemistry of Amino Acids, Peptides, and Proteins, XX, XX, Vol. 7, 1983, pages 268-357, XP002032461.			
	CB*	M. Llinas-Brunet, et al., "Peptide-Based Inhibitors of the Hepatitis C Virus Serine Protease," Bioorganic & Medicinal Chemistry Letters 8 (1998), pp 1713-1718.			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

509455